Related Experiment Video
Updated: Jul 7, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary arterial hypertension from a pediatric perspective
1University of Colorado Health Sciences Center, Department of Pathology, Denver, CO, USA. carlyne.cool@uchsc.edu
This review covers pediatric pulmonary arterial hypertension (PAH) in children. It discusses classification, histopathology, and causes like congenital heart disease and persistent pulmonary hypertension of the newborn.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Medical Genetics
Background:
- Pulmonary arterial hypertension (PAH) in children presents unique challenges.
- Understanding its classification and pathogenesis is crucial for effective management.
- Existing literature requires synthesis to provide a comprehensive pediatric focus.
Purpose of the Study:
- To provide a framework for understanding pediatric pulmonary hypertension.
- To review current classification schemes, including WHO recommendations.
- To explore the histopathology and diverse etiologies of childhood PAH.
Main Methods:
- Literature review and synthesis of existing research on pediatric pulmonary arterial hypertension.
- Discussion of World Health Organization (WHO) classification updates.
- Examination of histopathological findings in severe cases.
Main Results:
- Detailed review of idiopathic and familial forms of pediatric PAH.
- Analysis of specific childhood etiologies: persistent pulmonary hypertension of the newborn (PPHN) and congenital heart disease (CHD).
- Exploration of contributing factors: collagen vascular diseases, portal hypertension, and viral infections.
Conclusions:
- Pediatric PAH requires a tailored approach considering its unique causes and classifications.
- Further research into the pathogenesis of childhood PAH is warranted.
- Comprehensive understanding aids in developing targeted therapeutic strategies for pediatric patients.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Embolism I: Introduction
